{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:29:39Z","timestamp":1794565779051,"version":"4.9.1"},"reference-count":223,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1097\/ftd.0000000000000260","type":"journal-article","created":{"date-parts":[[2016,3,19]],"date-time":"2016-03-19T16:44:35Z","timestamp":1458405875000},"page":"143-169","source":"Crossref","is-referenced-by-count":135,"title":["Therapeutic Drug Monitoring of Everolimus"],"prefix":"10.1097","volume":"38","author":[{"given":"Maria","family":"Shipkova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis A.","family":"Hesselink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliane M.","family":"Billaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teun","family":"van Gelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142 K.","family":"Kunicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"Brunet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Budde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus J.","family":"Barten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"De Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eberhard","family":"Wieland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga Mill\u00e1n","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satohiro","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Seger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Picard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Oellerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loralie J.","family":"Langman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Wallemacq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond G.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Marquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210129","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/nyas.12122","article-title":". Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases.","volume":"1291","author":"Lebwohl","year":"2013","journal-title":"Ann N Y Acad Sci"},{"key":"R2-1-20210129","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00003088-200443020-00002","article-title":"Clinical pharmacokinetics of everolimus.","volume":"43","author":"Kirchner","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"R3-1-20210129","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/00007691-199512000-00011","article-title":". Consensus document: therapeutic monitoring of tacrolimus (FK-506).","volume":"17","author":"Jusko","year":"1995","journal-title":"Ther Drug Monit"},{"key":"R4-1-20210129","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/00007691-199512000-00017","article-title":". Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel.","volume":"17","author":"Oellerich","year":"1995","journal-title":"Ther Drug Monit"},{"key":"R5-1-20210129","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/00007691-199512000-00025","article-title":". Mycophenolate mofetil: a report of the consensus panel.","volume":"17","author":"Shaw","year":"1995","journal-title":"Ther Drug Monit"},{"key":"R6-1-20210129","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/00007691-199512000-00022","article-title":". Consensus guidelines for therapeutic drug monitoring of rapamycin: report of the consensus panel.","volume":"17","author":"Yatscoff","year":"1995","journal-title":"Ther Drug Monit"},{"key":"R7-1-20210129","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0009-9120(98)00049-6","article-title":". Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus.","volume":"31","author":"Oellerich","year":"1998","journal-title":"Clin Biochem"},{"key":"R8-1-20210129","first-page":"33","article-title":"Cyclosporin therapeutic drug monitoring-an established service revisited.","volume":"24","author":"Morris","year":"2003","journal-title":"Clin Biochem Rev"},{"key":"R9-1-20210129","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/01.ftd.0000199358.80013.bd","article-title":". Therapeutic drug monitoring of mycophenolate mofetil in transplantation.","volume":"28","author":"van Gelder","year":"2006","journal-title":"Ther Drug Monit"},{"key":"R10-1-20210129","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/FTD.0b013e318198d092","article-title":". Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference.","volume":"31","author":"Wallemacq","year":"2009","journal-title":"Ther Drug Monit"},{"key":"R11-1-20210129","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.transproceed.2011.03.018","article-title":". Once-a-day administration of everolimus is safe in de novo renal transplant recipients: 1-year results of a pilot study.","volume":"43","author":"Spagnoletti","year":"2011","journal-title":"Transplant Proc"},{"issue":"suppl 2","key":"R12-1-20210129","first-page":"319","article-title":". First pharmacokinetic evaluation of everolimus QD in thoracic transplant patients Abstract P675.","volume":"26","author":"Guillemain","year":"2013","journal-title":"Transpl Int"},{"key":"R13-1-20210129","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/S0041-1345(98)00587-9","article-title":". Chemical modification of rapamycin: the discovery of SDZ RAD.","volume":"30","author":"Sedrani","year":"1998","journal-title":"Transplant Proc"},{"key":"R15-1-20210129","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism.","volume":"124","author":"Wullschleger","year":"2006","journal-title":"Cell"},{"key":"R16-1-20210129","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa022171","article-title":". Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.","volume":"349","author":"Eisen","year":"2003","journal-title":"N Engl J Med"},{"key":"R17-1-20210129","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1517\/14740338.2010.511611","article-title":"Everolimus: efficacy and safety in cardiac transplantation.","volume":"9","author":"Schaffer","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"R18-1-20210129","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1093\/ndt\/gfh322","article-title":". Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients.","volume":"19","author":"Budde","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"R19-1-20210129","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1378\/chest.09-0780","article-title":". Diffuse alveolar hemorrhage induced by everolimus.","volume":"137","author":"Vandewiele","year":"2010","journal-title":"Chest"},{"key":"R20-1-20210129","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.athoracsur.2007.02.056","article-title":". Uneventful thoracic healing with everolimus after aortic valve replacement.","volume":"84","author":"Pascual","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"R21-1-20210129","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1681\/ASN.V1251059","article-title":". Pharmacokinetic interactions augment toxicities of sirolimuscyclosporine combinations.","volume":"12","author":"Podder","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"R22-1-20210129","first-page":"3632","article-title":"Gulias O, et al..","volume":"24","author":"Torras","year":"2009","journal-title":"Rapamycin has dual opposing effects on proteinuric experimental nephropathies: is it a matter of podocyte damage Nephrol Dial Transplant"},{"key":"R25-1-20210129","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/ajt.12181","article-title":". Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial.","volume":"13","author":"Eisen","year":"2013","journal-title":"Am J Transplant"},{"key":"R26-1-20210129","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/TP.0000000000000225","article-title":". Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine in de novo kidney recipients.","volume":"99","author":"Oh","year":"2015","journal-title":"Transplantation"},{"key":"R27-1-20210129","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(10)62318-5","article-title":". Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.","volume":"377","author":"Budde","year":"2011","journal-title":"Lancet"},{"key":"R28-1-20210129","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/ctr.12353","article-title":". Renal function preservation with the mTOR inhibitor, everolimus, after lung transplant.","volume":"28","author":"Schneer","year":"2014","journal-title":"Clin Transplant"},{"key":"R29-1-20210129","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1023\/A:1011940108365","article-title":"In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin.","volume":"15","author":"Crowe","year":"1998","journal-title":"Pharm Res"},{"key":"R30-1-20210129","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0090-9556(24)15260-9","article-title":". Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats.","volume":"27","author":"Crowe","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"R31-1-20210129","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/TP.0b013e31820ae4ac","article-title":". CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients.","volume":"91","author":"Picard","year":"2011","journal-title":"Transplantation"},{"key":"R32-1-20210129","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1067\/mcp.2001.112969","article-title":". Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.","volume":"69","author":"Kovarik","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"R33-1-20210129","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/FTD.0000000000000185","article-title":". Closer to the site of action; everolimus concentrations in peripheral blood mononuclear cells correlate well with whole blood concentrations.","volume":"37","author":"Robertsen","year":"2015","journal-title":"Ther Drug Monit"},{"key":"R34-1-20210129","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/FTD.0b013e3181570830","article-title":". Identification of everolimus metabolite patterns in trough blood samples of kidney transplant patients.","volume":"29","author":"Strom","year":"2007","journal-title":"Ther Drug Monit"},{"key":"R35-1-20210129","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/(SICI)1096-9888(200003)35:3<454::AID-JMS959>3.0.CO;2-K","article-title":". Isolation from pig liver microsomes, identification by tandem mass spectrometry and in vitro immunosuppressive activity of an SDZ-RAD 17,18,19,20,21,22-tris-epoxide.","volume":"35","author":"Lhoest","year":"2000","journal-title":"J Mass Spectrom"},{"key":"R36-1-20210129","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1124\/dmd.108.020651","article-title":". The macrolide everolimus forms an unusual metabolite in animals and humans: identification of a phosphocholine ester.","volume":"36","author":"Zollinger","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"R37-1-20210129","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/FTD.0b013e318273c899","article-title":". Population pharmacokinetics of everolimus in cardiac recipients: comedications, ABCB1, and CYP3A5 polymorphisms.","volume":"34","author":"Lemaitre","year":"2012","journal-title":"Ther Drug Monit"},{"key":"R38-1-20210129","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/11599710-000000000-00000","article-title":". Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients.","volume":"51","author":"Moes","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"R39-1-20210129","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1034\/j.1600-6143.2003.00107.x","article-title":". Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation.","volume":"3","author":"Kovarik","year":"2003","journal-title":"Am J Transplant"},{"key":"R40-1-20210129","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0009-9236(01)15633-X","article-title":". Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment.","volume":"70","author":"Kovarik","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"R41-1-20210129","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/01.ftd.0000175911.70172.2e","article-title":"The role of therapeutic monitoring of everolimus in solid organ transplantation.","volume":"27","author":"Mabasa","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R42-1-20210129","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/FTD.0b013e31829a7a7c","article-title":". Racial comparisons of everolimus pharmacokinetics and pharmacodynamics in adult kidney transplant recipients.","volume":"35","author":"Taber","year":"2013","journal-title":"Ther Drug Monit"},{"key":"R43-1-20210129","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/bdd.524","article-title":"Everolimus drug interactions: application of a classification system for clinical decision making.","volume":"27","author":"Kovarik","year":"2006","journal-title":"Biopharm Drug Dispos"},{"key":"R44-1-20210129","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1111\/j.1432-2277.2012.01561.x","article-title":". Management of rifamycins-everolimus drug-drug interactions in a liver-transplant patient with pulmonary tuberculosis.","volume":"25","author":"Lefeuvre","year":"2012","journal-title":"Transpl Int"},{"key":"R45-1-20210129","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00044011-200929070-00006","article-title":". Management of metabolic cytochrome P450 3A4 drug-drug interaction between everolimus and azole antifungals in a renal transplant patient.","volume":"29","author":"Billaud","year":"2009","journal-title":"Clin Drug Investig"},{"key":"R46-1-20210129","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2165\/00003088-200241110-00003","article-title":". Mechanisms of clinically relevant drug interactions associated with tacrolimus.","volume":"41","author":"Christians","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"R47-1-20210129","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/FTD.0b013e318161a335","article-title":". Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor.","volume":"30","author":"Brandhorst","year":"2008","journal-title":"Ther Drug Monit"},{"key":"R48-1-20210129","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/ctr.12045","article-title":". Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine.","volume":"27","author":"Shihab","year":"2013","journal-title":"Clin Transplant"},{"key":"R49-1-20210129","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1592\/phco.22.3.154.33542","article-title":". Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants.","volume":"22","author":"Kovarik","year":"2002","journal-title":"Pharmacotherapy"},{"key":"R50-1-20210129","first-page":"265","article-title":". Clinical pharmacokinetics in the 21st century.","volume":"34","author":"Ensom","year":"1998","journal-title":"Does the evidence support definitive outcomes Clin Pharmacokinet"},{"key":"R51-1-20210129","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/lt.21827","article-title":". Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.","volume":"15","author":"De Simone","year":"2009","journal-title":"Liver Transplant"},{"key":"R52-1-20210129","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/lt.22292","article-title":". Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis.","volume":"17","author":"Saliba","year":"2011","journal-title":"Liver Transplant"},{"key":"R53-1-20210129","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/TP.0b013e3181de1d67","article-title":". Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients.","volume":"90","author":"Chan","year":"2010","journal-title":"Transplantation"},{"key":"R54-1-20210129","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1111\/j.1600-6143.2011.03574.x","article-title":"How to use mTOR inhibitors the search goes on.","volume":"11","author":"Budde","year":"2011","journal-title":"Am J Transplant"},{"key":"R55-1-20210129","first-page":"728","article-title":"Switching from calcineurin inhibitors to mammalian target of rapamycin inhibitors-finally caught the right wave Transplantation.","volume":"92","author":"Naesens","year":"2011","journal-title":""},{"key":"R56-1-20210129","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.trim.2014.05.002","article-title":". Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.","volume":"31","author":"Shihab","year":"2014","journal-title":"Transpl Immunol"},{"key":"R57-1-20210129","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.trre.2010.01.005","article-title":". Clinical recommendations for the use of everolimus in heart transplantation.","volume":"24","author":"Manito","year":"2010","journal-title":"Transplant Rev (Orlando)"},{"key":"R58-1-20210129","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1432-2277.2010.01131.x","article-title":"Another step in defining the role of mTOR inhibitors in kidney transplantation.","volume":"23","author":"Flechner","year":"2010","journal-title":"Transpl Int"},{"key":"R59-1-20210129","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1432-2277.2009.00940.x","article-title":". Reduction of cyclosporine following the introduction of everolimus in maintenance heart transplant recipients: a pilot study.","volume":"23","author":"Ross","year":"2010","journal-title":"Transpl Int"},{"key":"R60-1-20210129","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/TP.0b013e318193886e","article-title":"The role of mTOR inhibitors in the management of posttransplant malignancy.","volume":"87","author":"Monaco","year":"2009","journal-title":"Transplantation"},{"key":"R61-1-20210129","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.trre.2013.06.001","article-title":". Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation.","volume":"27","author":"Peddi","year":"2013","journal-title":"Transplant Rev (Orlando)"},{"key":"R62-1-20210129","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1097\/00007890-200105270-00008","article-title":". RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection.","volume":"71","author":"Kahan","year":"2001","journal-title":"Transplantation"},{"key":"R63-1-20210129","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1097\/01.TP.0000141094.34903.54","article-title":". Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients.","volume":"78","author":"Vitko","year":"2004","journal-title":"Transplantation"},{"key":"R64-1-20210129","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.TP.0000164352.65613.24","article-title":". Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study.","volume":"80","author":"Lorber","year":"2005","journal-title":"Transplantation"},{"key":"R65-1-20210129","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1111\/j.1600-6143.2005.01063.x","article-title":". Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients.","volume":"5","author":"Vitko","year":"2005","journal-title":"Am J Transplant"},{"key":"R66-1-20210129","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/00007890-200203270-00016","article-title":". Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range.","volume":"73","author":"Kovarik","year":"2002","journal-title":"Transplantation"},{"key":"R67-1-20210129","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1517\/13543784.11.12.1845","article-title":"Review of the proliferation inhibitor everolimus.","volume":"11","author":"Nashan","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"key":"R68-1-20210129","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1399-0012.2005.00326.x","article-title":". Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data.","volume":"19","author":"Lorber","year":"2005","journal-title":"Clin Transplant"},{"key":"R69-1-20210129","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/tri.12275","article-title":". Interstitial pneumonitis caused by everolimus: a case-cohort study in renal transplant recipients.","volume":"27","author":"Baas","year":"2014","journal-title":"Transpl Int"},{"key":"R70-1-20210129","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1517\/14740338.2014.888056","article-title":". Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms.","volume":"13","author":"Duran","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"R71-1-20210129","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1600-6143.2004.00389.x","article-title":". Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies.","volume":"4","author":"Vitko","year":"2004","journal-title":"Am J Transplant"},{"key":"R72-1-20210129","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1432-2277.2006.00414.x","article-title":". 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients.","volume":"20","author":"Tedesco-Silva","year":"2007","journal-title":"Transpl Int"},{"key":"R73-1-20210129","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/00007691-200410000-00007","article-title":". Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation.","volume":"26","author":"Kovarik","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R74-1-20210129","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1600-6143.2010.03129.x","article-title":". Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients.","volume":"10","author":"Tedesco Silva","year":"2010","journal-title":"Am J Transplant"},{"key":"R75-1-20210129","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/TP.0b013e3182848e03","article-title":". Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.","volume":"95","author":"Cibrik","year":"2013","journal-title":"Transplantation"},{"key":"R76-1-20210129","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1600-6143.2012.04334.x","article-title":". The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes.","volume":"13","author":"Wiseman","year":"2013","journal-title":"Am J Transplant"},{"key":"R77-1-20210129","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1097\/TP.0b013e3181bb43ec","article-title":". Everolimus with very low-exposure cyclosporine A in de novo kidney transplantation: a multicenter, randomized, controlled trial.","volume":"88","author":"Salvadori","year":"2009","journal-title":"Transplantation"},{"key":"R78-1-20210129","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1097\/TP.0b013e318216c1db","article-title":". Everolimus and minimization of cyclosporine in renal transplantation: 24-month follow-up of the EVEREST study.","volume":"91","author":"Ponticelli","year":"2011","journal-title":"Transplantation"},{"key":"R79-1-20210129","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/j.1432-2277.2010.01094.x","article-title":". Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial.","volume":"23","author":"Dantal","year":"2010","journal-title":"Transpl Int"},{"key":"R80-1-20210129","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/TP.0b013e318166927b","article-title":". Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness.","volume":"85","author":"Chan","year":"2008","journal-title":"Transplantation"},{"key":"R81-1-20210129","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1432-2277.2012.01465.x","article-title":". Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation.","volume":"25","author":"Langer","year":"2012","journal-title":"Transpl Int"},{"key":"R82-1-20210129","doi-asserted-by":"crossref","first-page":"337","DOI":"10.12659\/AOT.890673","article-title":". The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study.","volume":"19","author":"Rostaing","year":"2014","journal-title":"Ann Transplant"},{"issue":"suppl 3","key":"R83-1-20210129","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/00007890-201407151-00249","article-title":". Efficacy and safety of everolimus with low-dose tacrolimus in de novo renal transplant recipients: 12-month randomized study Abstract 713.","volume":"14","author":"Qazi","year":"2014","journal-title":"Am J Transplant"},{"key":"R84-1-20210129","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/j.1600-6143.2012.03994.x","article-title":". Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study.","volume":"12","author":"Budde","year":"2012","journal-title":"Am J Transplant"},{"key":"R85-1-20210129","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/ajt.12952","article-title":". Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study.","volume":"15","author":"Budde","year":"2015","journal-title":"Am J Transplant"},{"key":"R86-1-20210129","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/j.1600-6143.2011.03961.x","article-title":". Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation.","volume":"12","author":"Liefeldt","year":"2012","journal-title":"Am J Transplant"},{"key":"R87-1-20210129","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/tri.12252","article-title":". A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients.","volume":"27","author":"Chadban","year":"2014","journal-title":"Transpl Int"},{"key":"R88-1-20210129","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1399-0012.2008.00795.x","article-title":". Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study.","volume":"22","author":"Holdaas","year":"2008","journal-title":"Clin Transplant"},{"key":"R89-1-20210129","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1111\/j.1600-6143.2012.04162.x","article-title":". Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation.","volume":"12","author":"Mjornstedt","year":"2012","journal-title":"Am J Transplant"},{"key":"R90-1-20210129","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/tri.12437","article-title":". Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation.","volume":"28","author":"Mjornstedt","year":"2015","journal-title":"Transpl Int"},{"key":"R91-1-20210129","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5414\/CN108444","article-title":". Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study.","volume":"83","author":"Budde","year":"2015","journal-title":"Clin Nephrol"},{"key":"R92-1-20210129","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40620-014-0134-4","article-title":". Renal function to 5 years after late conversion of kidney transplant patients to everolimus: a randomized trial.","volume":"28","author":"Budde","year":"2015","journal-title":"J Nephrol"},{"key":"R93-1-20210129","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/TP.0b013e318224c12d","article-title":". Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.","volume":"92","author":"Holdaas","year":"2011","journal-title":"Transplantation"},{"key":"R94-1-20210129","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/TP.0b013e3181af1df6","article-title":". Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.","volume":"88","author":"Bemelman","year":"2009","journal-title":"Transplantation"},{"key":"R95-1-20210129","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/FTD.0b013e3181e5c656","article-title":". Liquid chromatography-tandem mass spectrometry outperforms fluorescence polarization immunoassay in monitoring everolimus therapy in renal transplantation.","volume":"32","author":"Moes","year":"2010","journal-title":"Ther Drug Monit"},{"key":"R96-1-20210129","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/ajt.12543","article-title":". De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial.","volume":"14","author":"Asrani","year":"2014","journal-title":"Am J Transplant"},{"key":"R98-1-20210129","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1111\/j.1600-6143.2012.04212.x","article-title":". Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial.","volume":"12","author":"De Simone","year":"2012","journal-title":"Am J Transplant"},{"key":"R99-1-20210129","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/ajt.12280","article-title":". Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study.","volume":"13","author":"Saliba","year":"2013","journal-title":"Am J Transplant"},{"key":"R100-1-20210129","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1248\/bpb.b13-00234","article-title":". Effectiveness of sirolimus in combination with cyclosporine against chronic rejection in a pediatric liver transplant patient.","volume":"36","author":"Shinke","year":"2013","journal-title":"Biol Pharm Bull"},{"key":"R101-1-20210129","first-page":"1","article-title":". Effectiveness of everolimus in combination with cyclosporine as treatment for chronic rejection in a pediatric patient undergoing liver transplantation.","volume":"31","author":"Sato","year":"2014","journal-title":"Jpn J Ther Drug Monit"},{"key":"R102-1-20210129","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":". Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"key":"R103-1-20210129","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/tri.12372","article-title":". Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review.","volume":"27","author":"Cholongitas","year":"2014","journal-title":"Transpl Int"},{"key":"R104-1-20210129","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S1053-2498(02)01221-4","article-title":". Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure.","volume":"22","author":"Kovarik","year":"2003","journal-title":"J Heart Lung Transplant"},{"key":"R105-1-20210129","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1046\/j.1600-6143.2004.00601.x","article-title":". Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling.","volume":"4","author":"Starling","year":"2004","journal-title":"Am J Transplant"},{"key":"R106-1-20210129","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.healun.2007.02.008","article-title":". Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients.","volume":"26","author":"Lehmkuhl","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"R107-1-20210129","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/TP.0b013e3181aacd22","article-title":". Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.","volume":"88","author":"Lehmkuhl","year":"2009","journal-title":"Transplantation"},{"key":"R108-1-20210129","doi-asserted-by":"crossref","first-page":"535983","DOI":"10.1155\/2011\/535983","article-title":". Efficacy and safety of low-dose cyclosporine with everolimus and steroids in de novo heart transplant patients: a multicentre, randomized trial.","volume":"2011","author":"Zuckermann","year":"2011","journal-title":"J Transplant"},{"key":"R109-1-20210129","doi-asserted-by":"crossref","first-page":"683964","DOI":"10.1155\/2013\/683964","article-title":". Everolimus in heart transplantation: an update.","volume":"2013","author":"Hirt","year":"2013","journal-title":"J Transplant"},{"key":"R110-1-20210129","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1111\/ajt.12809","article-title":". Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial.","volume":"14","author":"Andreassen","year":"2014","journal-title":"Am J Transplant"},{"issue":"suppl 3","key":"R112-1-20210129","first-page":"S46","article-title":". A multi-center, randomized, open-label, parallel group phase IV trial investigating the outcome on renal function, efficacy and safety of CNI-reduction or elimination with everolimus in de novo heart transplant recipients: the MANDELA study design Abstract P107.","volume":"27","author":"Deuse","year":"2014","journal-title":"Transpl Int"},{"key":"R113-1-20210129","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1097\/01.TP.0000064083.02120.2C","article-title":". Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation.","volume":"75","author":"King-Biggs","year":"2003","journal-title":"Transplantation"},{"key":"R114-1-20210129","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S1053-2498(03)00309-7","article-title":". Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression.","volume":"23","author":"Groetzner","year":"2004","journal-title":"J Heart Lung Transplant"},{"key":"R115-1-20210129","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.trre.2012.11.001","article-title":". Recommendations on the use of everolimus in lung transplantation.","volume":"27","author":"de Pablo","year":"2013","journal-title":"Transplant Rev (Orlando)"},{"key":"R116-1-20210129","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.critrevonc.2005.03.012","article-title":"Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy.","volume":"56","author":"Taylor","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"R117-1-20210129","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1111\/j.1600-6143.2005.00863.x","article-title":". Everolimus alters the bronchoalveolar lavage and endobronchial biopsy immunologic profile post-human lung transplantation.","volume":"5","author":"Snell","year":"2005","journal-title":"Am J Transplant"},{"key":"R118-1-20210129","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1600-6143.2005.01134.x","article-title":". Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial.","volume":"6","author":"Snell","year":"2006","journal-title":"Am J Transplant"},{"key":"R119-1-20210129","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.transproceed.2009.12.004","article-title":"Everolimus in lung transplantation in Chile.","volume":"42","author":"Parada","year":"2010","journal-title":"Transplant Proc"},{"key":"R120-1-20210129","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.healun.2014.06.001","article-title":". Three-year results of an investigator-driven multicenter, international, randomized open-label de novo trial to prevent BOS after lung transplantation.","volume":"34","author":"Glanville","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"R122-1-20210129","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/TP.0b013e3181cbac2d","article-title":". Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.","volume":"89","author":"Gullestad","year":"2010","journal-title":"Transplantation"},{"key":"R123-1-20210129","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1097\/TP.0b013e3181fd01b7","article-title":". Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial.","volume":"90","author":"Gullestad","year":"2010","journal-title":"Transplantation"},{"key":"R124-1-20210129","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.healun.2011.12.010","article-title":". Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate.","volume":"31","author":"Arora","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"R125-1-20210129","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1111\/j.1600-6143.2012.04234.x","article-title":". Virtual histology assessment of cardiac allograft vasculopathy following introduction of everolimus-results of a multicenter trial.","volume":"12","author":"Arora","year":"2012","journal-title":"Am J Transplant"},{"key":"R127-1-20210129","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1200\/JCO.2007.14.0988","article-title":". Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.","volume":"26","author":"ODonnell","year":"2008","journal-title":"J Clin Oncol"},{"key":"R128-1-20210129","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1200\/JCO.2007.15.5192","article-title":"Dose selection in phase I studies: why we should always go for the top.","volume":"26","author":"Sleijfer","year":"2008","journal-title":"J Clin Oncol"},{"key":"R129-1-20210129","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1200\/JCO.2007.14.5482","article-title":". Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.","volume":"26","author":"Tabernero","year":"2008","journal-title":"J Clin Oncol"},{"key":"R130-1-20210129","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":". Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"R131-1-20210129","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00280-014-2435-7","article-title":". Impact of everolimus blood concentration on its anti-cancer activity in patients with metastatic renal cell carcinoma.","volume":"73","author":"Thiery-Vuillemin","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"R132-1-20210129","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":". Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"R133-1-20210129","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S1470-2045(14)70138-X","article-title":". Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.","volume":"15","author":"Andre","year":"2014","journal-title":"Lancet Oncol"},{"key":"R134-1-20210129","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1093\/annonc\/mdu456","article-title":". Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2.","volume":"25","author":"Piccart","year":"2014","journal-title":"Ann Oncol"},{"key":"R135-1-20210129","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":". Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"key":"R136-1-20210129","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/petr.12147","article-title":". Growing experience with mTOR inhibitors in pediatric solid organ transplantation.","volume":"17","author":"Ganschow","year":"2013","journal-title":"Pediatr Transplant"},{"key":"R137-1-20210129","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/petr.12035","article-title":". De novo therapy with everolimus and reduced-exposure cyclosporine following pediatric kidney transplantation: a prospective, multicenter, 12-month study.","volume":"17","author":"Grushkin","year":"2013","journal-title":"Pediatr Transplant"},{"key":"R138-1-20210129","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1111\/j.1600-6143.2010.03266.x","article-title":". De novo therapy with everolimus, low-dose ciclosporine A, basiliximab and steroid elimination in pediatric kidney transplantation.","volume":"10","author":"Pape","year":"2010","journal-title":"Am J Transplant"},{"key":"R139-1-20210129","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/TP.0b013e3182295bed","article-title":". Pediatric kidney transplantation followed by de novo therapy with everolimus, low-dose cyclosporine A, and steroid elimination: 3-year data.","volume":"92","author":"Pape","year":"2011","journal-title":"Transplantation"},{"key":"R140-1-20210129","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/petr.12261","article-title":". Three-yr safety and efficacy of everolimus and low-dose cyclosporine in de novo pediatric kidney transplant patients.","volume":"18","author":"Ferraresso","year":"2014","journal-title":"Pediatr Transplant"},{"key":"R142-1-20210129","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/petr.12268","article-title":"The use of everolimus in pediatric kidney transplantation.","volume":"18","author":"Tonshoff","year":"2014","journal-title":"Pediatr Transplant"},{"key":"R143-1-20210129","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1053\/j.ajkd.2011.10.013","article-title":"Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition.","volume":"59","author":"Budde","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"R144-1-20210129","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":". Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"key":"R145-1-20210129","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S1470-2045(14)70489-9","article-title":". Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study.","volume":"15","author":"Franz","year":"2014","journal-title":"Lancet Oncol"},{"key":"R146-1-20210129","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":". Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"key":"R149-1-20210129","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","article-title":"Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference.","volume":"49","author":"Krueger","year":"2013","journal-title":"Pediatr Neurol"},{"key":"R150-1-20210129","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1086\/674311","article-title":". Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trial.","volume":"3","author":"Seyfarth","year":"2013","journal-title":"Pulm Circ"},{"key":"R151-1-20210129","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1128\/MCB.01581-08","article-title":". NF2merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.","volume":"29","author":"James","year":"2009","journal-title":"Mol Cell Biol"},{"key":"R152-1-20210129","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/neuonc\/not150","article-title":". Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas.","volume":"16","author":"Karajannis","year":"2014","journal-title":"Neuro Oncol"},{"key":"R153-1-20210129","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11060-014-1710-0","article-title":". Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas.","volume":"122","author":"Goutagny","year":"2015","journal-title":"J Neurooncol"},{"key":"R154-1-20210129","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0041-1345(00)02116-3","article-title":". Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD.","volume":"33","author":"Jacobsen","year":"2001","journal-title":"Transplant Proc"},{"key":"R155-1-20210129","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.bcp.2009.02.013","article-title":". Disposition of everolimus in mdr1a-1b- mice and after a pre-treatment of lapatinib in Swiss mice.","volume":"77","author":"Chu","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"R156-1-20210129","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1472-8206.2011.00957.x","article-title":". Sirolimus and everolimus intestinal absorption and interaction with calcineurin inhibitors: a differential effect between cyclosporine and tacrolimus.","volume":"26","author":"Lamoureux","year":"2012","journal-title":"Fundam Clin Pharmacol"},{"key":"R157-1-20210129","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3109\/00498254.2011.573882","article-title":". Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters.","volume":"41","author":"Picard","year":"2011","journal-title":"Xenobiotica"},{"key":"R158-1-20210129","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/ctr.12350","article-title":". The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients.","volume":"28","author":"Schoeppler","year":"2014","journal-title":"Clin Transplant"},{"key":"R159-1-20210129","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/jnci\/91.18.1588","article-title":". Response: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.","volume":"91","author":"Amirimani","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"R160-1-20210129","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/em.10199","article-title":". Increased transcriptional activity of the CYP3A41B promoter variant.","volume":"42","author":"Amirimani","year":"2003","journal-title":"Environ Mol Mutagen"},{"key":"R161-1-20210129","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00008571-200207000-00003","article-title":". The CYP3A41B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer.","volume":"12","author":"Spurdle","year":"2002","journal-title":"Pharmacogenetics"},{"key":"R162-1-20210129","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/tpj.2010.28","article-title":". Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs.","volume":"11","author":"Wang","year":"2011","journal-title":"Pharmacogenomics J"},{"key":"R163-1-20210129","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1038\/psp.2013.78","article-title":". Effect of CYP3A422, CYP3A53, and CYP3A combined genotypes on cyclosporine, everolimus, and tacrolimus pharmacokinetics in renal transplantation.","volume":"3","author":"Moes","year":"2014","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"R164-1-20210129","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/TP.0b013e3181fa94a0","article-title":". Haplotypic arrangement in CYP3A locus is associated with side effects of proliferative signal inhibitors in renal transplant recipients.","volume":"91","author":"Bandur","year":"2011","journal-title":"Transplantation"},{"key":"R165-1-20210129","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1399-0012.2009.01198.x","article-title":". The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation.","volume":"25","author":"Kniepeiss","year":"2011","journal-title":"Clin Transplant"},{"key":"R166-1-20210129","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00508-013-0387-2","article-title":". The role of CYP2C8 genotypes in dose requirement and levels of everolimus after heart transplantation.","volume":"125","author":"Kniepeiss","year":"2013","journal-title":"Wien Klin Wochenschr"},{"key":"R168-1-20210129","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4161\/cbt.2.3.360","article-title":"Rapamycins: mechanism of action and cellular resistance.","volume":"2","author":"Huang","year":"2003","journal-title":"Cancer Biol Ther"},{"key":"R169-1-20210129","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/FPC.0b013e328357359d","article-title":". Association of sirolimus adverse effects with m-TOR, p70S6K or Raptor polymorphisms in kidney transplant recipients.","volume":"22","author":"Woillard","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"R170-1-20210129","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cyto.2008.02.015","article-title":". Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients.","volume":"42","author":"Bohler","year":"2008","journal-title":"Cytokine"},{"key":"R171-1-20210129","first-page":"660","article-title":". Effect of immunosuppressants on CD26dipetidyl peptidase IV expression on CD3 cells in vitro Abstract P530.","volume":"31","author":"Shipkova","year":"2009","journal-title":"Ther Drug Monit"},{"key":"R172-1-20210129","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1016\/j.transproceed.2010.07.045","article-title":". Number of peripheral blood regulatory T cells and lymphocyte activation at 3 months after conversion to mTOR inhibitor therapy.","volume":"42","author":"San Segundo","year":"2010","journal-title":"Transplant Proc"},{"key":"R173-1-20210129","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/cyto.a.22019","article-title":". Immunological advantages of everolimus versus cyclosporin A in liver-transplanted recipients, as revealed by polychromatic flow cytometry.","volume":"81","author":"Roat","year":"2012","journal-title":"Cytometry A"},{"key":"R174-1-20210129","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/ctr.12331","article-title":". Utility of immune monitoring in heart transplant recipients on everolimus-based immune suppression.","volume":"28","author":"Ben Gal","year":"2014","journal-title":"Clin Transplant"},{"key":"R175-1-20210129","doi-asserted-by":"crossref","first-page":"e89449","DOI":"10.1371\/journal.pone.0089449","article-title":". The relevance of testing the efficacy of anti-angiogenesis treatments on cells derived from primary tumors: a new method for the personalized treatment of renal cell carcinoma.","volume":"9","author":"Grepin","year":"2014","journal-title":"PLoS One"},{"key":"R176-1-20210129","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/cyto.b.21005","article-title":". Assay validation of phosphorylated S6 ribosomal protein for a pharmacodynamic monitoring of mTOR-inhibitors in peripheral human blood.","volume":"82","author":"Dieterlen","year":"2012","journal-title":"Cytometry B Clin Cytom"},{"key":"R177-1-20210129","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/0076-6879(91)00146-N","article-title":"Purification and properties of mitogen-activated S6 kinase from rat liver and 3T3 cells.","volume":"200","author":"Lane","year":"1991","journal-title":"Methods Enzymol"},{"key":"R178-1-20210129","first-page":"3058","article-title":"P70 S6 kinase assay: a pharmacodynamic monitoring strategy for rapamycin; assay development.","volume":"28","author":"Gallant","year":"1996","journal-title":"Transplant Proc"},{"key":"R179-1-20210129","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1053\/j.ajkd.2007.05.002","article-title":". Monitoring biological action of rapamycin in renal transplantation.","volume":"50","author":"Leogrande","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"R180-1-20210129","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/0008-5472.CAN-3554-2","article-title":". Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.","volume":"64","author":"Boulay","year":"2004","journal-title":"Cancer Res"},{"key":"R181-1-20210129","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/TP.0000000000000273","article-title":". Pharmacodynamic monitoring of mammalian target of rapamycin inhibition by phosphoflow cytometric determination of p70S6 kinase activity.","volume":"99","author":"Hoerning","year":"2015","journal-title":"Transplantation"},{"key":"R182-1-20210129","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0378-4347(98)00426-5","article-title":". Development of a high-performance liquid chromatographic-electrospray mass spectrometric assay for the specific and sensitive quantification of the novel immunosuppressive macrolide 40-O-(2-hydroxyethyl)rapamycin.","volume":"720","author":"Segarra","year":"1998","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"R183-1-20210129","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/039463200802100206","article-title":". Stability of sirolimus and everolimus measured by immunoassay techniques in whole blood samples from kidney transplant patients.","volume":"21","author":"Capone","year":"2008","journal-title":"Int J Immunopathol Pharmacol"},{"key":"R184-1-20210129","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jchromb.2013.03.014","article-title":". Two rapid ultra performance liquid chromatographytandem mass spectrometry (UPLCMSMS) methods with common sample pretreatment for therapeutic drug monitoring of immunosuppressants compared to immunoassay.","volume":"928","author":"Tszyrsznic","year":"2013","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R185-1-20210129","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1373\/clinchem.2005.051151","article-title":"Simultaneous measurement of sirolimus and everolimus in whole blood by HPLC with ultraviolet detection.","volume":"51","author":"Khoschsorur","year":"2005","journal-title":"Clin Chem"},{"key":"R186-1-20210129","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.clinbiochem.2006.03.019","article-title":". Evaluation of a fluorescent polarization immunoassay for whole blood everolimus determination using samples from renal transplant recipients.","volume":"39","author":"Salm","year":"2006","journal-title":"Clin Biochem"},{"key":"R187-1-20210129","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S1570-0232(02)00107-1","article-title":". Quantification and stability of everolimus (SDZ RAD) in human blood by high-performance liquid chromatography-electrospray tandem mass spectrometry.","volume":"772","author":"Salm","year":"2002","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R188-1-20210129","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jchromb.2004.11.016","article-title":". High-performance liquid chromatography with ultraviolet detection for therapeutic drug monitoring of everolimus.","volume":"816","author":"Baldelli","year":"2005","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R189-1-20210129","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/FTD.0b013e318192304c","article-title":"Robust, high-throughput LC-MSMS method for therapeutic drug monitoring of cyclosporine, tacrolimus, everolimus, and sirolimus in whole blood.","volume":"31","author":"Koster","year":"2009","journal-title":"Ther Drug Monit"},{"key":"R190-1-20210129","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jpba.2008.11.021","article-title":". Therapeutic drug monitoring of everolimus using the dried blood spot method in combination with liquid chromatography-mass spectrometry.","volume":"50","author":"van der Heijden","year":"2009","journal-title":"J Pharm Biomed Anal"},{"key":"R191-1-20210129","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.talanta.2013.04.027","article-title":". Fast LC-MSMS analysis of tacrolimus, sirolimus, everolimus and cyclosporin A in dried blood spots and the influence of the hematocrit and immunosuppressant concentration on recovery.","volume":"115","author":"Koster","year":"2013","journal-title":"Talanta"},{"key":"R192-1-20210129","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1046\/j.1365-2125.1999.00085.x","article-title":". Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients.","volume":"48","author":"Neumayer","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"R193-1-20210129","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2165\/00003495-200666040-00009","article-title":"Everolimus: a review of its use in renal and cardiac transplantation.","volume":"66","author":"Dunn","year":"2006","journal-title":"Drugs"},{"key":"R194-1-20210129","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/ndt\/gfu013","article-title":". The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, phase 3 trial EXIST-1.","volume":"29","author":"Kingswood","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"R195-1-20210129","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/clinchem\/44.6.1275","article-title":". Automated simultaneous quantification of the immunosuppressants 40-O-(2-hydroxyethyl) rapamycin and cyclosporine in blood with electrospray-mass spectrometric detection.","volume":"44","author":"Vidal","year":"1998","journal-title":"Clin Chem"},{"key":"R196-1-20210129","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1515\/CCLM.2002.045","article-title":". Simultaneous quantification of sirolimus, everolimus, tacrolimus and cyclosporine by liquid chromatography-mass spectrometry (LC-MS).","volume":"40","author":"Deters","year":"2002","journal-title":"Clin Chem Lab Med"},{"key":"R197-1-20210129","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/clinchem\/48.6.955","article-title":"Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus, and cyclosporin A in whole blood.","volume":"48","author":"Streit","year":"2002","journal-title":"Clin Chem"},{"key":"R198-1-20210129","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.cca.2005.07.019","article-title":". Simultaneous determination of everolimus and cyclosporine concentrations by HPLC with ultraviolet detection.","volume":"364","author":"Baldelli","year":"2006","journal-title":"Clin Chim Acta"},{"key":"R199-1-20210129","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1007\/s00216-012-6317-8","article-title":". Analysis of cyclosporin A, tacrolimus, sirolimus, and everolimus in dried blood spot samples using liquid chromatography tandem mass spectrometry.","volume":"404","author":"den Burger","year":"2012","journal-title":"Anal Bioanal Chem"},{"key":"R200-1-20210129","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00007691-200404000-00023","article-title":"Therapeutic drug monitoring of immunosuppressant drugs by high-performance liquid chromatography-mass spectrometry.","volume":"26","author":"Taylor","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R201-1-20210129","first-page":"61","article-title":"Review of the newest HPLC methods with mass spectrometry detection for determination of immunosuppressive drugs in clinical practice.","volume":"14","author":"Korecka","year":"2009","journal-title":"Ann Transplant"},{"key":"R202-1-20210129","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jchromb.2011.09.041","article-title":"Therapeutic drug monitoring and LC-MSMS.","volume":"883-","author":"Adaway","year":"2012","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R203-1-20210129","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1373\/clinchem.2004.037416","article-title":"Simple extraction protocol for analysis of immunosuppressant drugs in whole blood.","volume":"50","author":"Annesley","year":"2004","journal-title":"Clin Chem"},{"key":"R204-1-20210129","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nprot.2009.25","article-title":". A rapid HPLC-MSMS method for the simultaneous quantification of cyclosporine A, tacrolimus, sirolimus and everolimus in human blood samples.","volume":"4","author":"Seger","year":"2009","journal-title":"Nat Protoc"},{"key":"R205-1-20210129","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1472-6904-12-2","article-title":"Validation of an LC-MSMS method to determine five immunosuppressants with deuterated internal standards including MPA.","volume":"12","author":"Buchwald","year":"2012","journal-title":"BMC Clin Pharmacol"},{"key":"R206-1-20210129","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/FTD.0000000000000006","article-title":"A direct method for the measurement of everolimus and sirolimus in whole blood by LC-MSMS using an isotopic everolimus internal standard.","volume":"36","author":"Morgan","year":"2014","journal-title":"Ther Drug Monit"},{"key":"R207-1-20210129","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/FTD.0b013e318283403e","article-title":"Comparison of a stable isotope-labeled and an analog internal standard for the quantification of everolimus by a liquid chromatography-tandem mass spectrometry method.","volume":"35","author":"Heideloff","year":"2013","journal-title":"Ther Drug Monit"},{"key":"R209-1-20210129","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1373\/clinchem.2009.138602","article-title":"Pitfalls associated with the use of liquid chromatography-tandem mass spectrometry in the clinical laboratory.","volume":"56","author":"Vogeser","year":"2010","journal-title":"Clin Chem"},{"key":"R210-1-20210129","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.clinbiochem.2004.11.007","article-title":"Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry.","volume":"38","author":"Taylor","year":"2005","journal-title":"Clin Biochem"},{"key":"R211-1-20210129","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1515\/CCLM.2011.669","article-title":". Evaluation of the MassTrak Immunosuppressant XE Kit for the determination of everolimus and cyclosporin A in human whole blood employing isotopically labeled internal standards.","volume":"49","author":"Ji","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"R212-1-20210129","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/FTD.0b013e318274827d","article-title":"Evaluation of a novel commercial assay for the determination of cyclosporine A, tacrolimus, sirolimus, and everolimus by liquid chromatography-tandem mass spectrometric assay.","volume":"35","author":"Becker","year":"2013","journal-title":"Ther Drug Monit"},{"key":"R215-1-20210129","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cca.2007.01.017","article-title":". Comparison of fluorescent polarization immunoassay (FPIA) versus HPLC to measure everolimus blood concentrations in clinical transplantation.","volume":"380","author":"Khoschsorur","year":"2007","journal-title":"Clin Chim Acta"},{"key":"R217-1-20210129","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/FTD.0b013e31820afc97","article-title":"Evaluation of QMS everolimus assay using Hitachi 917 Analyzer: comparison with liquid chromatographymass spectrometry.","volume":"33","author":"Dasgupta","year":"2011","journal-title":"Ther Drug Monit"},{"key":"R218-1-20210129","first-page":"542","article-title":"Application of new QMS everolimus assay performed on CDx 90 analyzer (ThermoFisher) to therapeutic drug monitoring in transplant patients Abstract P237.","volume":"33","author":"Kunicki","year":"2011","journal-title":"Ther Drug Monit"},{"key":"R219-1-20210129","first-page":"542","article-title":"Evaluation of Thermo Scientific QMS everolimus immunoassy reagent Abstract P235.","volume":"33","author":"Smith","year":"2011","journal-title":"Ther Drug Monit"},{"key":"R220-1-20210129","first-page":"542","article-title":"Zufi[Combining Acute Accent]a L, Iba[Combining Acute Accent]n[Combining Tilde]ez N, Aldaz A. Comparison of everolimus measured by different immunoassay methods Abstract P236.","volume":"33","year":"2011","journal-title":"Ther Drug Monit"},{"key":"R224-1-20210129","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/FTD.0b013e3182a3b3f6","article-title":". Analytical performance of QMS everolimus assay on ortho Vitros 5,1 FS fusion analyzer: measuring everolimus trough levels for solid organ transplant recipients.","volume":"36","author":"Shu","year":"2014","journal-title":"Ther Drug Monit"},{"key":"R227-1-20210129","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/FTD.0000000000000057","article-title":". Latex-enhanced turbidimetric immunoassay for everolimus in whole blood using the Nanopia TDM everolimus assay with the JCA-BM6010 automatic analyzer.","volume":"36","author":"Mori","year":"2014","journal-title":"Ther Drug Monit"},{"key":"R228-1-20210129","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/FTD.0000000000000133","article-title":". Evaluation of QMS everolimus assay using Indiko analyzer: comparison with an ultra-performance liquid chromatography tandem mass spectrometry (UPLCMSMS) method.","volume":"37","author":"Buthiau","year":"2015","journal-title":"Ther Drug Monit"},{"key":"R229-1-20210129","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/FTD.0000000000000191","article-title":". Long-term cross-validation of everolimus therapeutic drug monitoring assays: the Zortracker study.","volume":"37","author":"Schniedewind","year":"2015","journal-title":"Ther Drug Monit"},{"key":"R230-1-20210129","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/FTD.0000000000000126","article-title":". Comparison of everolimus QMS immunoassay on Architect ci4100 and liquid chromatographymass spectrometry: lack of agreement in organ transplanted patients.","volume":"37","author":"Hoffer","year":"2015","journal-title":"Ther Drug Monit"},{"key":"R232-1-20210129","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.clinbiochem.2006.08.005","article-title":"Determination of everolimus in whole blood using the Abbott IMx sirolimus microparticle enzyme immunoassay.","volume":"40","author":"Bouzas","year":"2007","journal-title":"Clin Biochem"},{"key":"R233-1-20210129","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/039463200802100311","article-title":". Quantification of sirolimus and everolimus by immunoassay techniques: test specificity and cross-reactivity evaluation.","volume":"21","author":"Pieri","year":"2008","journal-title":"Int J Immunopathol Pharmacol"},{"key":"R234-1-20210129","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.transproceed.2010.01.059","article-title":". Relationship between everolimus blood concentration assessed using the Innofluor Certican Fluorescence Polarization Immunoassay and the Architect i System sirolimus chemiluminescent microparticle immunoassay.","volume":"42","author":"Coentrao","year":"2010","journal-title":"Transplant Proc"},{"key":"R235-1-20210129","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/jcla.20459","article-title":". Rapid estimation of whole blood everolimus concentrations using architect sirolimus immunoassay and mathematical equations: comparison with everolimus values determined by liquid chromatographymass spectrometry.","volume":"25","author":"Dasgupta","year":"2011","journal-title":"J Clin Lab Anal"},{"key":"R236-1-20210129","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3109\/00365513.2011.646300","article-title":"Determination of everolimus in blood samples from kidney and liver transplant recipients using the sirolimus chemiluminescence magnetic microparticle immunoassay (CMIA) on the Architect-i1000(R) system.","volume":"72","author":"Hermida-Cadahia","year":"2012","journal-title":"Scand J Clin Lab Invest"},{"key":"R237-1-20210129","first-page":"403","article-title":"Determination of blood everolimus concentrations in kidney and liver transplant recipients using the sirolimus antibody conjugated magnetic immunoassay (ACMIA).","volume":"57","author":"Bouzas","year":"2011","journal-title":"Clin Lab"},{"key":"R238-1-20210129","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1373\/clinchem.2011.172080","article-title":". The need for standardization of tacrolimus assays.","volume":"57","author":"Levine","year":"2011","journal-title":"Clin Chem"},{"key":"R239-1-20210129","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1373\/clinchem.2013.209114","article-title":". Standardization of LC-MS for therapeutic drug monitoring of tacrolimus.","volume":"59","author":"Annesley","year":"2013","journal-title":"Clin Chem"},{"key":"R240-1-20210129","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":". Reduced exposure to calcineurin inhibitors in renal transplantation.","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"R241-1-20210129","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1097\/TP.0b013e3181a23cb2","article-title":". The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony study.","volume":"87","author":"Ekberg","year":"2009","journal-title":"Transplantation"},{"key":"R242-1-20210129","first-page":"709","article-title":"A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I.","volume":"21","author":"Passing","year":"1983","journal-title":"J Clin Chem Clin Biochem"},{"key":"R243-1-20210129","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/clinchem\/39.3.424","article-title":"Evaluation of regression procedures for methods comparison studies.","volume":"39","author":"Linnet","year":"1993","journal-title":"Clin Chem"},{"key":"R244-1-20210129","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/00007691-199512000-00006","article-title":". Analytic requirements for immunosuppressive drugs in clinical trials.","volume":"17","author":"Shaw","year":"1995","journal-title":"Ther Drug Monit"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000260","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T21:23:15Z","timestamp":1748812995000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201604000-00001"}},"subtitle":["A Consensus Report"],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":223,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000260","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}